Monteblist-LA Tablet SR is a once-daily, controlled-release formulation that combines the therapeutic benefits of ambroxol, levocetirizine, and montelukast in a single tablet. This potent combination addresses the multifaceted needs of patients suffering from chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and allergic rhinitis. Ambroxol, a mucolytic agent, helps break down thick mucus, while levocetirizine, a second-generation antihistamine, effectively alleviates symptoms of allergic rhinitis, including itching, sneezing, and runny nose. Montelukast, a leukotriene receptor antagonist, inhibits the production of inflammatory mediators, thereby reducing airway constriction and inflammation. The sustained-release technology ensures a prolonged therapeutic effect, with ambroxol and montelukast providing up to 12 hours of activity, and levocetirizine offering a peak concentration at 6-8 hours. This synergistic combination provides comprehensive relief from respiratory symptoms, including cough, shortness of breath, and wheezing, making Monteblist-LA Tablet SR an excellent treatment option for patients seeking long-term management of their respiratory conditions.